Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection

• Published in: International journal of molecular sciences Vol. 18; no. 4; p. 845
• Main Authors: Ferrer-Batallé, Montserrat, Llop, Esther, Ramírez, Manel, Aleixandre, Rosa Núria, Saez, Marc, Comet, Josep, de Llorens, Rafael, Peracaula, Rosa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17-04-2017; MDPI (Multidisciplinary Digital Publishing Institute); MDPI
• Subjects: Adult; Aged; Antigens; Benign; Biomarkers; Biomarkers, Tumor; Blood; Cancer; Càncer; Diagnosis; Diagnostic software; Diagnostic systems; Diagnòstic; Differential diagnosis; Follow-Up Studies; Glicosilació; Glycosylation; Humans; Hyperplasia; Isoforms; Male; Middle Aged; N-Acetylneuraminic Acid; Neoplasm Grading; Patients; Prostate; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Hyperplasia - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Pròstata; Recurrence; Risk; ROC Curve; Severity of Illness Index; Tumors; PHI; prostate cancer; α2,3-sialic acid; diagnosis; glycosylation; proPSA; prostate specific antigen
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms18040845

Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions.